Abstract
Malarial disease mainly caused by the Plasmodium falciparum is creating a worsened situation for mankind, and there were around 214 million new cases of malaria in 2015 (range 149-303 million) all over the world. Now, it has become the challenging task to sort out the problem because malarial parasites are becoming increasingly resistant to several antimalarial drugs. In vitro intercalated compounds Actinomycin, Cyclophosphamide, Camptothecin, and Genistein were evaluated on Plasmodium falciparum 3D7 strain using parasite culture assay and SYBER Green fluorescence assay. The 3D7 strain was used since genes from the parasite genome have been extensively used in vaccine development and other studies. Based on fluorescence assay, SYBR green I (SG) dye was used for screening the antimalarial compounds against malaria parasite 3D7. In the present study, we have studied the parasite growth inhibition by Actinomycin, Cyclophosphamide, Camptothecin, and Genistein to find out which intercalating agent is the most effective against Plasmodium falciparum 3D7 strain. We found in our observation that Actinomycin showed maximum inhibition of the parasite Plasmodium falciparum 3D7 strain growth. The analysis that was done for the effective and alternative antimalarial drugs with minimal side effects, had stimulated the identification of a novel targeted drug. We also analyzed and reported that the antiplasmodial activity of Actinomycin is novel as compared to the previously described Intercalating Compounds.